PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Di Leo, Angelo
TI  - CONFIRM Trial Final Analysis of Overall Survival: Fulvestrant 500 versus 250 mg
DP  - 2013 Mar 01
TA  - MD Conference Express
PG  - 12--13
VI  - 12
IP  - 20
4099  - http://mdc.sagepub.com/content/12/20/12.short
4100  - http://mdc.sagepub.com/content/12/20/12.full
AB  - The Comparison of Fulvestrant 250 mg and 500 mg in Postmenopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy [CONFIRM] trial compared treatment with 2 doses of fulvestrant (250 vs 500 mg) in postmenopausal women with locally advanced or metastatic estrogen receptor (ER)-positive breast cancer that had recurred or progressed after endocrine therapy. The primary analysis showed that progression-free survival was significantly increased with fulvestrant 500 versus 250 mg [Di Leo A et al. J Clin Oncol 2010]. This article discusses the final analysis of overall survival.